Entresto vs Biktarvy
Side-by-side drug price comparison from Medicare Part D data
Verdict
Entresto costs 90% less per claim than Biktarvy ($379.00 vs $3746.00). Neither drug has a generic alternative available. Total Medicare spending: Entresto at $4.8B vs Biktarvy at $3.8B.
| Metric | Entresto | Biktarvy |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $379* | $3,746 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.8B | $3.8B |
| Total Claims | 12,560,000 | 1,020,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 18.3% | 12.8%* |
| Generic Available | No | No |
| Condition | Heart Failure | HIV |
| Total Beneficiaries | 1,085,000 | 85,000 |
Entresto costs 90% less per claim than Biktarvy ($379.00 vs $3746.00). Neither drug has a generic alternative available. Total Medicare spending: Entresto at $4.8B vs Biktarvy at $3.8B.
Explore More
Comparing Entresto and Biktarvy on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.